MacroGenics Inc at JPMorgan Healthcare Conference Transcript
Hello, everyone. Welcome. My name is (inaudible) I'm associated at JPMorgan. It's my pleasure to introduce our speaker for today, Scott Koenig, CEO and President of MacroGenics.
With that, I'll hand over to Scott to get started.
Well, thank you very much, [Pasi,] and thank you to JPMorgan for the invitation to present today. I'll be making forward-looking statements during the presentation. So please refer to our SEC filings to understand the risks associated with an investment in MacroGenics.
Despite the challenges in the marketplace for the industry at large this past year, in 2022, we were able to build upon our significant achievements of our clinical and preclinical pipeline, initiate multiple partnerships, advanced multiple collaborations and extend our runway through upfront in-licensing payments milestones as well as the internal consolidation of our employees in multiple facilities. So in 2023, we see great opportunities for advancing both our pipelines
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
